New treatment tested to stop rare blood disorder from coming back
NCT ID NCT04074187
Summary
This study tested whether a drug called caplacizumab could prevent acquired thrombotic thrombocytopenic purpura (aTTP), a rare and serious blood clotting disorder, from coming back in Japanese patients. The trial involved 21 adults who were already receiving standard treatment for aTTP. Researchers measured if adding caplacizumab reduced disease recurrence, helped restore normal platelet counts, and improved safety outcomes over several months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 3920001
Kitakyushu-Shi, Japan
-
Investigational Site Number 3920002
Kumamoto, Japan
-
Investigational Site Number 3920003
Kurashiki-Shi, Japan
-
Investigational Site Number 3920005
Maebashi, Japan
-
Investigational Site Number 3920006
Sendai, Japan
-
Investigational Site Number 3920007
Kashihara-shi, Japan
-
Investigational Site Number 3920009
Iruma-Gun, Japan
-
Investigational Site Number 3920010
Kyoto, Japan
-
Investigational Site Number 3920011
Osaka, Japan
-
Investigational Site Number 3920013
Kawasaki-Shi, Japan
-
Investigational Site Number 3920014
Kanazawa, Japan
-
Investigational Site Number 3920015
Nagoya, Japan
Conditions
Explore the condition pages connected to this study.